Compare Sibanye Stillwater Ltd (SBSW) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs Viatris Inc — how do they compare? Sibanye Stillwater Ltd trades at $12.85 (market cap $9.31B), while Viatris Inc trades at $16.5 (market cap $18.95B). The key difference: Viatris Inc is far larger — about 2× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (6.17%). Which is the better fit depends on your goals.
| SBSW | VTRS | |
|---|---|---|
Market Cap | $9.31B | $18.95B |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $17.86 |
52-Week Low | $8.00 | $9.49 |
Enterprise Value | $10.24B | $31.07B |
Dividend Yield | 6.17% | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBSW trades at $12.90, up 0.86% with a bullish technical signal. The company shows strong operational momentum with 54% YoY revenue growth and 111% EBITDA growth in H1 2026. Valuation metrics appear attractive with P/E of 10.2 and P/S of 0.88. Analyst consensus is mixed with 43% buy ratings and $14.00 price target, while technical indicators show bullish moving averages and neutral oscillators.
The outlook suggests potential upside from current levels supported by strong H1 2026 results and disciplined capital allocation. Key risks include commodity price volatility and the company's recent history of net losses. The stock presents a turnaround opportunity with improving cash flow trends and operational efficiency gains.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
